Aldebaran Therapeutics
Biotechnology ResearchView the employees at
Aldebaran Therapeutics-
Andrew Peterson Chief Executive Officer at Broadwing Bio
-
South San Francisco
-
Top 5%
Chris Pacheco (he/him) Executive Partner at 82VS | Alloy Therapeutics Venture Studio-
Top 10%
-
Overview
Aldebaran Therapeutics leverages human genetics and best-in-class antisense oligonucleotide (ASO) technology to deliver life-changing, precision ocular ASO medicines. Our focus on differentiated ASO technology, powered by Alloy Therapeutics' Genetic Medicines platform and novel AntiClastic™ ASO format, paves the way for a unique and rapid path to meaningful ocular solutions for patients.